Abstract

The Dana-Farber Cancer Institute (DFCI) and Dana-Farber/Partners CancerCare (DF/PCC) proposes to use its membership in the Cancer and Leukemia Group B (CALGB) to support participation in therapeautic research and other clinical trials, both in the Institute and its affiliate institutions. The goals of this project will be the initiation and participation in Phase I, II and III cooperative clinical trials involving chemotherapy, surgery and radiation therapy. A major emphasis will be made in developing new therapeutic strategies both at DFCI, MGH and in pilot collaborative investigations with interested membersof CALGB. Dana-Farber investigators would continue to be actively involved in disease and modality committees of the CALGB. This project is designed to bring cooperative group trials to regional community hospitals affilaitedthrough the Dana-Farber Cancer Institute throughout New England.

Public Health Relevance

With this application we propose to continue the collaborative DF/PCC efforts within CALGB and continue to make significant contributions to advancing oncology clinical research. We intend to continue the tradition set forth in Dana-Farber's previous grants of piloting studies in-house and subsequently bringing tested concepts to the Group for consideration as CALGB Phase II and III trials.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA032291-31
Application #
8247171
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1982-04-01
Project End
2015-03-31
Budget Start
2012-04-25
Budget End
2013-03-31
Support Year
31
Fiscal Year
2012
Total Cost
$495,751
Indirect Cost
$241,320

  Institution

Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215

  Publications

Morrison, Vicki A; McCall, Linda; Muss, Hyman B et al. (2018) The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436). J Geriatr Oncol 9:228-234
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Fuchs, Charles S; Niedzwiecki, Donna; Mamon, Harvey J et al. (2017) Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol 35:3671-3677
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Freedman, Rachel A; Seisler, D K; Foster, J C et al. (2017) Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat 161:363-373
Stone, Richard M; Mandrekar, Sumithra J; Sanford, Ben L et al. (2017) Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 377:454-464
Katz, Matthew H G; Ou, Fang-Shu; Herman, Joseph M et al. (2017) Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer 17:505
Bluethmann, Shirley M; Alfano, Catherine M; Clapp, Jonathan D et al. (2017) Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance). Breast Cancer Res Treat 165:677-686

Showing the most recent 10 out of 228 publications